Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FQWJ4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $51,064
Award facts
- Contract value 100% obligated
- $51,064.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $51,064.08 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for 120 capsules of XTANDI 40 MG, an oncology medication used to treat advanced prostate cancer. This delivery order, issued on January 5, 2026, with an ultimate completion date of January 6, 2026, carries no set-aside designation and will be performed in Park Ridge, Illinois. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, has been registered in the System for Award Management since 2001 and maintains established relationships with federal agencies through its pharmaceutical distribution operations.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that authorizes the company to supply pharmaceuticals, biologics, and medical consumables to Department of Defense healthcare facilities worldwide. The parent IDC, designated SPE2DR with a $499,999,999 ceiling, positions DMS Pharmaceutical Group as a critical regional pharmaceutical supplier supporting military healthcare operations through a 30-month base period with three optional 30-month extension periods extending through December 31, 2036. The company's demonstrated performance across numerous delivery orders for specialized pharmaceuticals including oncology treatments, biologics, and emergency medications reflects its capability to fulfill diverse military medical supply requirements.
Quick answers
Who was awarded contract SPE2DR26FQWJ4?
SPE2DR26FQWJ4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 5, 2026.
How much is contract SPE2DR26FQWJ4 worth?
The government has obligated $51,064 on SPE2DR26FQWJ4.
Is contract SPE2DR26FQWJ4 an order under another contract?
Yes. SPE2DR26FQWJ4 is a delivery order under SPE2DR25D9353, an indefinite delivery contract.
Was contract SPE2DR26FQWJ4 competed?
The extent of competition for SPE2DR26FQWJ4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award